Safety and immunogenicity of REMUNE in HIV-infected Thai subjects.

Abstract

The safety and immunogenicity of REMUNE, an HIV-specific immune based therapy for HIV infection, was evaluated in a cohort of 30 HIV infected subjects in Thailand. This therapy utilizes a gp120 depleted inactivated virus (HZ321), which exhibits a high degree of conservation with the core antigens of both type B' and E strains of HIV, the predominant Thailand isolates. The treatment was well tolerated, with no serious adverse events reported over the course of the 4-month trial. Treatment in which four doses were administered with REMUNE appeared to boost HIV-specific immune responses, with approximately 75% of the treated subjects demonstrating an increase in either the repertoire or the intensity of the serological response to HIV as measured by Western blot. CD4%, viral load, and weight remained stable over the course of the 4-month study relative to baseline values. Viral subtyping of this cohort revealed a predominance of type 'E'. These data suggest that REMUNE is safe and immunogenic in seropositive Thai subjects and supports further study of the therapeutic potential of REMUNE to treat HIV-1 infection.

• Authors: A Limsuwan, V Churdboonchart, R B Moss, W Sirawaraporn, R Sutthent, B Smutharaks, D Glidden, R Trauger, G Theofan, D Carlo
• Journal: Vaccine (Vaccine) 1998 Jan-Feb Vol. 16 Issue 2-3 Pg. 142-9 ISSN: 0264-410X [Print] Netherlands
• PMID: 9607022 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• AIDS Vaccines
• RNA, Viral
• remune

Topics

• AIDS Vaccines (immunology, therapeutic use)
• Adult
• Amino Acid Sequence
• CD4 Lymphocyte Count
• Female
• HIV Infections (blood, immunology, prevention & control)
• HIV-1 (genetics, immunology)
• Humans
• Immunization
• Male
• Molecular Sequence Data
• RNA, Viral (blood)
• Thailand